EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis

•There is a strong rationale for targeting EGFR-pathway in NSCLC.•Addition of EGFR-mAbs to CT provided clinical benefit to patients with NSCLC.•EGFR FISH/IHC identify sub-populations which benefit from the addition of EGFR-mAb.•Results of combining EGFR-mAbs and RT in many clinical trials remain controversial.•Role of histology-driven, biomarker-enriched model based on EGFR-FISH and IHC.